Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.

Giannico GA, Gown AM, Epstein JI, Revetta F, Bishop JA.

Hum Pathol. 2017 Sep;67:152-159. doi: 10.1016/j.humpath.2017.07.002. Epub 2017 Jul 13.

PMID:
28711650
2.

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.

Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, Butnor KJ, Chirieac LR, Churg AM, Dacic S, Galateau-Sallé F, Gibbs A, Gown AM, Krausz T, Litzky LA, Marchevsky A, Nicholson AG, Roggli VL, Sharma AK, Travis WD, Walts AE, Wick MR.

Arch Pathol Lab Med. 2018 Jan;142(1):89-108. doi: 10.5858/arpa.2017-0124-RA. Epub 2017 Jul 7.

PMID:
28686500
3.
4.

Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.

Sheffield BS, Fulton R, Kalloger SE, Milne K, Geller G, Jones M, Jacquemont C, Zachara S, Zhao E, Pleasance E, Laskin J, Jones SJ, Marra MA, Yip S, Nelson BH, Gown AM, Ho C, Ionescu DN.

J Histochem Cytochem. 2016 Oct;64(10):587-600. doi: 10.1369/0022155416665338. Epub 2016 Sep 2.

5.

Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It.

Gown AM.

Arch Pathol Lab Med. 2016 Sep;140(9):893-8. doi: 10.5858/arpa.2016-0119-RA. Review.

PMID:
27575264
6.

Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.

Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Enos RA, Fineberg S, Focke CM, Gao D, Gown AM, Grabau D, Gutierrez C, Hugh JC, Kos Z, Lænkholm AV, Lin MG, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Viale G, Hayes DF, McShane LM, Dowsett M.

NPJ Breast Cancer. 2016 May 18;2:16014. doi: 10.1038/npjbcancer.2016.14. eCollection 2016.

7.

BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas.

Hwang HC, Pyott S, Rodriguez S, Cindric A, Carr A, Michelsen C, Thompson K, Tse CH, Gown AM, Churg A.

Am J Surg Pathol. 2016 May;40(5):714-8. doi: 10.1097/PAS.0000000000000616.

PMID:
26900815
9.

Markers of metastatic carcinoma of breast origin.

Gown AM, Fulton RS, Kandalaft PL.

Histopathology. 2016 Jan;68(1):86-95. doi: 10.1111/his.12877. Review.

PMID:
26768031
10.

Vascular mesangial channels in human nodular diabetic glomerulopathy.

Cossey LN, Hennigar RA, Bonsib S, Gown AM, Silva FG.

Hum Pathol. 2016 Feb;48:148-53. doi: 10.1016/j.humpath.2015.09.018. Epub 2015 Oct 3.

PMID:
26596585
11.

Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site.

Kandalaft PL, Gown AM.

Arch Pathol Lab Med. 2016 Jun;140(6):508-23. doi: 10.5858/arpa.2015-0173-CP. Epub 2015 Oct 12.

PMID:
26457625
12.

Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.

Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A.

Am J Surg Pathol. 2016 Jan;40(1):120-6. doi: 10.1097/PAS.0000000000000529.

PMID:
26448191
13.

Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen.

Menke JR, Raleigh DR, Gown AM, Thomas S, Perry A, Tihan T.

Acta Neuropathol. 2015 Sep;130(3):441-3. doi: 10.1007/s00401-015-1459-3. Epub 2015 Jul 21. No abstract available.

PMID:
26195322
14.

Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing.

Sheffield BS, Tinker AV, Shen Y, Hwang H, Li-Chang HH, Pleasance E, Ch'ng C, Lum A, Lorette J, McConnell YJ, Sun S, Jones SJ, Gown AM, Huntsman DG, Schaeffer DF, Churg A, Yip S, Laskin J, Marra MA.

PLoS One. 2015 Mar 23;10(3):e0119689. doi: 10.1371/journal.pone.0119689. eCollection 2015.

15.

An international study to increase concordance in Ki67 scoring.

Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Lænkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO.

Mod Pathol. 2015 Jun;28(6):778-86. doi: 10.1038/modpathol.2015.38. Epub 2015 Feb 20.

16.

BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.

Sheffield BS, Hwang HC, Lee AF, Thompson K, Rodriguez S, Tse CH, Gown AM, Churg A.

Am J Surg Pathol. 2015 Jul;39(7):977-82. doi: 10.1097/PAS.0000000000000394.

PMID:
25634745
17.

The lung-restricted marker napsin A is highly expressed in clear cell carcinomas of the ovary.

Kandalaft PL, Gown AM, Isacson C.

Am J Clin Pathol. 2014 Dec;142(6):830-6. doi: 10.1309/AJCP8WO2EOIAHSOF.

PMID:
25389337
18.

GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.

Banet N, Gown AM, Shih IeM, Kay Li Q, Roden RB, Nucci MR, Cheng L, Przybycin CG, Nasseri-Nik N, Wu LS, Netto GJ, Ronnett BM, Vang R.

Am J Surg Pathol. 2015 Jan;39(1):101-8. doi: 10.1097/PAS.0000000000000315.

19.

PAX8 expression in uterine adenocarcinomas and mesonephric proliferations.

Yemelyanova A, Gown AM, Wu LS, Holmes BJ, Ronnett BM, Vang R.

Int J Gynecol Pathol. 2014 Sep;33(5):492-9. doi: 10.1097/PGP.0b013e3182a54afa.

PMID:
25083965
20.

Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.

Mohanty SK, Smith SC, Chang E, Luthringer DJ, Gown AM, Aron M, Amin MB.

Am J Clin Pathol. 2014 Aug;142(2):173-83. doi: 10.1309/AJCPK1OV6IMNPFGL.

PMID:
25015857
21.

PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma).

Holmes BJ, Gown AM, Vang R, Ronnett BM, Yemelyanova A.

Int J Gynecol Pathol. 2014 Jul;33(4):425-31. doi: 10.1097/PGP.0b013e31829d7705.

PMID:
24901404
22.

An international Ki67 reproducibility study.

Polley MY, Leung SC, McShane LM, Gao D, Hugh JC, Mastropasqua MG, Viale G, Zabaglo LA, Penault-Llorca F, Bartlett JM, Gown AM, Symmans WF, Piper T, Mehl E, Enos RA, Hayes DF, Dowsett M, Nielsen TO; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group.

J Natl Cancer Inst. 2013 Dec 18;105(24):1897-906. doi: 10.1093/jnci/djt306. Epub 2013 Nov 7.

23.

Diagnostic Approach to Hepatic Mass Lesions and Role of Immunohistochemistry.

Marginean EC, Gown AM, Jain D.

Surg Pathol Clin. 2013 Jun;6(2):333-65. doi: 10.1016/j.path.2013.03.005. Epub 2013 May 4.

PMID:
26838978
24.

Immunohistochemical characterization of squamous differentiation and morular metaplasia in uterine endometrioid adenocarcinoma.

Blanco LZ Jr, Heagley DE, Lee JC, Gown AM, Gattuso P, Rotmensch J, Guirguis A, Dewdney S, Bitterman P.

Int J Gynecol Pathol. 2013 May;32(3):283-92. doi: 10.1097/PGP.0b013e31826129e1.

PMID:
23518912
25.

Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.

Oliva E, Pinheiro NF, Heney NM, Kaufman DS, Shipley WU, Gurski C, Spicer B, Paner GP, Gown AM, Amin MB.

Hum Pathol. 2013 May;44(5):860-6. doi: 10.1016/j.humpath.2012.08.011. Epub 2012 Nov 27.

PMID:
23199526
26.

IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations.

Lee AF, Gown AM, Churg A.

Am J Surg Pathol. 2013 Mar;37(3):421-6. doi: 10.1097/PAS.0b013e31826ab1c0.

PMID:
23108021
27.

Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship.

Gupta R, Billis A, Shah RB, Moch H, Osunkoya AO, Jochum W, Hes O, Bacchi CE, de Castro MG, Hansel DE, Zhou M, Vankalakunti M, Salles PG, Cabrera RA, Gown AM, Amin MB.

Am J Surg Pathol. 2012 Sep;36(9):1265-78.

PMID:
22895263
28.

Concordance between human epidermal growth factor receptor 2 testing by reverse transcriptase polymerase chain reaction and fluorescent in situ hybridization.

Gown AM, Goldstein LC, Hwang HC, Tse CH.

J Clin Oncol. 2012 May 10;30(14):1726-7; author reply 1728-9. doi: 10.1200/JCO.2011.41.0092. Epub 2012 Apr 9. No abstract available.

PMID:
22493420
29.

Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.

Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ, Gown AM.

J Clin Oncol. 2011 Nov 1;29(31):4168-74. doi: 10.1200/JCO.2011.36.0107. Epub 2011 Sep 26.

PMID:
21947821
30.

The knowns and the unknowns in HER2 testing in breast cancer.

Gown AM, Goldstein LC.

Am J Clin Pathol. 2011 Jul;136(1):5-6. doi: 10.1309/AJCP53KBPMDRTYDK. No abstract available.

PMID:
21685025
31.

Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology.

Dewar R, Fadare O, Gilmore H, Gown AM.

Arch Pathol Lab Med. 2011 Apr;135(4):422-9. doi: 10.1043/2010-0336-CP.1. Review.

PMID:
21466356
32.

Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?

Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM.

Breast Cancer Res Treat. 2012 Jan;131(2):413-24. doi: 10.1007/s10549-011-1416-3. Epub 2011 Mar 3.

PMID:
21369717
33.

Fixation time does not affect expression of HER2/neu.

Goldsmith JD, Allred DC, Beasley MB, Eisen R, Fulton RS, Gown AM, Hammond ME.

Am J Clin Pathol. 2011 Mar;135(3):484; author reply 485. doi: 10.1309/AJCPO1ZG6FERBGZB. No abstract available.

PMID:
21350107
34.

Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification.

Nese N, Martignoni G, Fletcher CD, Gupta R, Pan CC, Kim H, Ro JY, Hwang IS, Sato K, Bonetti F, Pea M, Amin MB, Hes O, Svec A, Kida M, Vankalakunti M, Berel D, Rogatko A, Gown AM, Amin MB.

Am J Surg Pathol. 2011 Feb;35(2):161-76. doi: 10.1097/PAS.0b013e318206f2a9.

PMID:
21263237
35.

Thyroid transcription factor-1 expression in breast carcinomas.

Robens J, Goldstein L, Gown AM, Schnitt SJ.

Am J Surg Pathol. 2010 Dec;34(12):1881-5. doi: 10.1097/PAS.0b013e3181f884e8.

PMID:
21107096
36.

Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.

Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN.

Am J Surg Pathol. 2010 Dec;34(12):1805-11. doi: 10.1097/PAS.0b013e3181f7dae3.

PMID:
21107086
37.

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP Jr, Goldstein LC, Gown AM, Habel LA.

J Clin Oncol. 2010 Oct 1;28(28):4300-6. doi: 10.1200/JCO.2009.24.8211. Epub 2010 Aug 9.

PMID:
20697093
38.

Diagnostic utility of galectin-3 in thyroid cancer.

Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, Nabi IR, Wiseman SM.

Am J Pathol. 2010 May;176(5):2067-81. doi: 10.2353/ajpath.2010.090353. Epub 2010 Apr 2. Review.

39.

Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients.

Collins LC, Achacoso N, Nekhlyudov L, Fletcher SW, Haque R, Quesenberry CP Jr, Puligandla B, Alshak NS, Goldstein LC, Gown AM, Schnitt SJ, Habel LA.

Am J Surg Pathol. 2009 Dec;33(12):1802-8.

40.

Tweaking and nudging toward improved-IHC quality.

Gown AM.

Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):363-5. doi: 10.1097/PAI.0b013e3181b4518f. No abstract available.

PMID:
19701082
41.

Personalized medicine-molecular targeted cancer therapy.

Osamura RY, Gown AM.

J Cell Mol Med. 2009 Nov-Dec;13(11-12):4285. doi: 10.1111/j.1582-4934.2009.00880.x. Epub 2009 Aug 19. No abstract available.

42.

Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.

Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR.

Arch Pathol Lab Med. 2009 Aug;133(8):1317-31. doi: 10.1043/1543-2165-133.8.1317.

PMID:
19653732
43.

Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry.

Terry J, Torlakovic EE, Garratt J, Miller D, Köbel M, Cooper J, Bahzad S, Pilavdzic D, O'Malley F, O'Brien AE, SenGupta S, Alport E, Têtu B, Knight B, Pettigrew NM, Berendt R, Wolber R, Trotter MJ, Riddell RH, Gaboury L, Elms F, Magliocco A, Barnes P, Gown AM, Gilks CB.

Appl Immunohistochem Mol Morphol. 2009 Oct;17(5):375-82. doi: 10.1097/PAI.0b013e31819adacf.

PMID:
19363444
44.

Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.

Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM, Huntsman D, Olivotto IA, Nielsen TO, Gelmon K.

J Clin Oncol. 2008 Dec 10;26(35):5697-704. doi: 10.1200/JCO.2007.15.8659. Epub 2008 Nov 10.

PMID:
19001334
45.

Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder.

Westfall DE, Folpe AL, Paner GP, Oliva E, Goldstein L, Alsabeh R, Gown AM, Amin MB.

Am J Surg Pathol. 2009 Jan;33(1):99-105. doi: 10.1097/PAS.0b013e318180c899.

PMID:
18941404
46.

Biomarker panel diagnosis of thyroid cancer: a critical review.

Griffith OL, Chiu CG, Gown AM, Jones SJ, Wiseman SM.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1399-413. doi: 10.1586/14737140.8.9.1399. Review.

PMID:
18759692
47.

Current issues in ER and HER2 testing by IHC in breast cancer.

Gown AM.

Mod Pathol. 2008 May;21 Suppl 2:S8-S15. doi: 10.1038/modpathol.2008.34. Review.

48.

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system.

Gown AM, Goldstein LC, Barry TS, Kussick SJ, Kandalaft PL, Kim PM, Tse CC.

Mod Pathol. 2008 Oct;21(10):1271-7. doi: 10.1038/modpathol.2008.83. Epub 2008 May 16.

49.

Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall.

Bahrami A, Gown AM, Baird GS, Hicks MJ, Folpe AL.

Mod Pathol. 2008 Jul;21(7):795-806. doi: 10.1038/modpathol.2008.86. Epub 2008 May 16.

50.

HER2 in well differentiated breast cancer: is testing necessary?

Haines GK 3rd, Wiley E, Susnik B, Apple SK, Frkovic-Grazio S, Reyes C, Goldstein LC, Dadmanesh F, Gown AM, Nadji M, Bracko M, Tavassoli FA.

Breast Cancer Res Treat. 2008 Dec;112(3):551-6. doi: 10.1007/s10549-008-9893-8. Epub 2008 Jan 18.

PMID:
18202913

Supplemental Content

Support Center